Published in
Wiley, British Journal of Dermatology, 3(187), p. 417-419, 2022
DOI: 10.1111/bjd.21066
Links
Tools
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa
Journal article published in 2022 by
Simon W. Jiang 
,
Jeffery T. Kwock ,
Beiyu Liu ,
Amy J. Petty ,
Aaron T. Zhao,
Cynthia L. Green ,
Tarannum Jaleel
,
Jeffery T. Kwock ,
Beiyu Liu ,
Amy J. Petty ,
Aaron T. Zhao,
Cynthia L. Green ,
Tarannum Jaleel
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.